Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IntegraSyn™ Cannabinoid Manufacturing Process - How it Works
Midas Letter broadcast Oct 13 2017
President and CEO Eric Adams talks to James about the Canadian cannabinoid market, patenting, and their research on oils to treat a rare skin disorder often first seen on children.
[url][/url][tag]insert-text-here[/tag]https://www.midasletter.com/2017/10/inmed-president-ceo-eric-adams-future-treating-disease-cannabinoids/
InMed Pharmaceuticals Files Provisional Patent for Pain Program
VANCOUVER, Oct. 3, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the company's intellectual and commercial property.
While there are numerous pharmaceutical products to treat both acute and chronic pain, the increase in the number of prescriptions for the opioid class of products (oxycodone, hydrocodone, morphine, methadone, fentanyl, etc.) has led to concerns as these products can be highly addictive and have damaging side effects, including death. According to the United States Centers for Disease Control and Prevention, drug overdose deaths continue to increase in the United States, with the majority (more than 60%) involving an opioid. Since 1999, the number of overdose deaths involving opioids (including prescription opioids and heroin) quadrupled, as have the number of prescriptions for opioids, yet there has been no increase in the amount of pain reported in the general population. Thus, there is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed is researching the potential of non-THC (tetrahydrocannabinol, a psychoactive ingredient in cannabis) cannabinoids to treat pain using a proprietary topical formulation.
"There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects," said Dr. Sazzad Hossain, Chief Scientific Officer of InMed Pharmaceuticals and a co-inventor on the patent. "InMed's focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management."
InMed's study results published earlier this year by InMed in the European Journal of Pain (NR July 27, 2017) highlighted the topical application of THC to successfully treat peripheral pain. The foundation of this patent is the unreported data on non-THC cannabinoids and their ability to modulate pain. The patent cites a range of cannabinoids, alone or in combination, applied topically to treat various types of pain – muscle, nerve, arthritis-induced joint pain, etc.
[url][/url][tag]insert-text-here[/tag]http://www.newswire.ca/news-releases/inmed-pharmaceuticals-files-provisional-patent-for-pain-program-649194803.html
InMed Retains Consultant Ben Paterson for Biosynthesis Development
VANCOUVER, Sept. 19, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for InMed's cannabinoid biosynthesis program. Ben Paterson is Principal Consultant at PatersonChemE Consulting, LLC.
Mr. Paterson has nearly four decades of experience in developing pharmaceutical manufacturing and purification processes. He was previously a Senior Engineering Advisor with Eli Lilly and Company, where he spent 37 years, including 24 years in their biosynthesis division. His expertise includes first defining processes in the lab, then scaling up to pilot and commercial scale. Mr. Paterson has conducted design, construction, operation, optimization, and troubleshooting of both large and small molecule drug facilities including the E. coli biosynthesis of numerous products. He brings experience in the seamless integration of biochemistry, equipment, and process control to successfully define a "process" at scale.
"Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design," said Eric A. Adams, President & CEO, "His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed."
Mr. Paterson earned his BSc. in Chemical Engineering from Northwestern University.
About PatersonChemE Consulting, LLC
PatersonChemE® provides process engineering consulting across the lifecycle of diverse manufacturing processes. PatersonChemE® offers process engineering consulting services for biotech, pharmaceutical, and chemical processing, from lab to commercial, from design to troubleshooting. Learn more at: http://www.patersoncheme.com
[url][/url][tag]insert-text-here[/tag]http://www.prnewswire.com/news-releases/inmed-retains-consultant-ben-paterson-for-biosynthesis-development-645628233.html
InMed Announces Agreement to Advance a Topical Formulation of INM-750
CSE: IN
OCTQB: IMLFF
VANCOUVER, June 13, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce it has signed an agreement with Pharmaseed Ltd, Israel's largest GLP-certified pre-clinical contract research organization, to develop a final formulation for InMed's lead compound, INM-750, a proprietary, topical cannabinoid product candidate intended as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications.
"This agreement with Pharmaseed now adds one of Israel's leading formulation development teams to our efforts and represents an important strategic relationship as we move INM-750 towards our first clinical trial," stated Eric A. Adams, CEO of InMed.
Under the agreement, Pharmaseed will develop a final formulation for INM-750 for continued R&D including IND-enabling pharmacology and toxicology studies and subsequent clinical studies. Also included under the scope of the contract is the development of assay methods for manufacturing, stability, quality assurance and other analytical methods.
About Pharmaseed
Pharmaseed is Israel's largest GLP private research organization leading in the development of life-science early stage technologies from discovery to the first in man/patient stage. The company specializes in both efficacy proof-of-concept studies and safety evaluation in various animal models, as well as complementary formulation development and in vitro/ex-vivo services. Its core competence lies in the area of translational and regenerative medical projects with main expertise in: Stem Cell, CNS, Pain, Cancer, Angiogenesis, Inflammation, Dermatology, Metabolic disorders, Infectious diseases and Medical devices. Over 50% (40) of the company's employee have PhD degrees representing many years of experience in academic and applied scientific research activity.
[url][/url][tag]insert-text-here[/tag]http://www.newswire.ca/news-releases/inmed-announces-agreement-to-advance-a-topical-formulation-of-inm-750-628151143.html
InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery
VANCOUVER, May 10, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of a provisional patent application in the United States for INM-085 as a cannabinoid-based topical therapy for glaucoma, which is an important step in providing intellectual and commercial protection for this therapy.
Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. Worldwide, it is the second-leading cause of blindness, and the current global market for drug therapies to treat glaucoma exceeds US$5 billion. Risk factors for glaucoma include increased pressure in the eye, a family history of the condition, migraines, high blood pressure, and obesity. Investigators studying patient adherence to glaucoma medications have identified multiple factors related to poor adherence, including more frequent and complex dosing regimens.
InMed is developing a stimulus-responsive, nanoparticle-laden vehicle for controlled delivery of ophthalmic drugs into the aqueous humor of the eye. The first applications of this vehicle will be for INM-085 as a cannabinoid-based topical therapy to reduce the intraocular pressure associated with glaucoma. INM-085 is intended for application as a once-per-day eye drop administered immediately prior to the patient's bedtime, intending to assist in reducing the high rate of non-adherence with current glaucoma therapies. Additionally, this novel, proprietary delivery system for ophthalmic drugs may also play an important role in enabling other companies' proprietary ophthalmic drug candidates or re-invigorating the commercial potential of off-patent products that would benefit from a once-a-day dosing regimen. InMed plans to initiate discussion with potential partners to this end.
www.newswire.ca/news-releases/inmed-pharmaceuticals-files-provisional-patent-application-for-ophthalmic-drug-delivery-621862393.html
Metabolic Engineering
InMed Announces Update on Biosynthesis Project
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today an update on its biosynthesis program.
The goal of InMed's biosynthesis program is to provide an alternate low cost and high quality process for producing phytocannabinoids for its product candidates. Typically, phytocannabinoids are extracted from the cannabis plant. The extraction process can be expensive, and can result in unwanted by-products and impurities. Using metabolic engineering the plant pathway for producing cannabinoids can be recreated in a microbial host and will be devoid of the by-products and impurities seen with extraction. The process can also be performed at industrial-scale allowing for a low cost production of cannabinoids.
Dr. Sazzad Hossain states "We have made great progress in the last 8 months developing a comprehensive de novo biosynthesis system for cannabinoids using a multiple metabolic engineering approach and have been able to produce our target cannabinoids on a gram scale basis. Successful production of our target cannabinoids using a biosynthetic process is a significant achievement for InMed and is an important step for our product development program".
InMed has filed a patent application covering its inventions in the organic and enzymatic synthesis of cannabinoids.
To review a presentation on InMed's biosynthesis program please click here: http://www.inmedpharma.com/s/presentations.asp
About Metabolic Engineering
Metabolic engineering can be defined as the modification of a cell's metabolic network for increased production of a specific molecule. Metabolic engineering simply re-creates the plant pathway in a microbial host, thereby allowing industrial-scale exploitation of the pathway for production of natural products. Many of pitfalls associated with plant extraction techniques are avoided. Importantly, unlike plant extraction, metabolic engineering allows manipulation of the pathway composition to tweak the final composition of the products. Not only is it a higher-yielding and more resource-efficient manufacturing platform, but the bioprocess and products face less obstacles when it comes to regulatory approval.
[url][/url][tag]insert-text-here[/tag]http://www.marketwired.com/press-release/inmed-announces-update-on-biosynthesis-project-cnsx-in-2096801.htm
Schedule 1
The following Patents families are the subject of the purchase agreement:
1. I107-0002 – Compositions and methods for treating epidermolysis bullosa simplex on
April 20, 2015;
2. I107-0003 - Composition and methods for treating eye diseases on May 7, 2015; and
3. I107-0004 – Metabolic Engineering of Cannabinoids on May 26, 2015.
Sedar.com page 6
Mar 28 2017 14:27:40 ET Material document(s)
[url][/url][tag]insert-text-here[/tag]http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00005782
Sedar.com
Facilities
InMed currently outsources the majority of our research and development activities. We access lab space through existing service contracts at UBC in the Department of Pharmaceutical Sciences and The Department of Chemical and Biological Engineering as well as the University of Debrecen, Hungary. InMed’s headquarters is a leased office space in downtown Vancouver.
Mar 28 2017 14:27:40 ET Annual information form – English PDF
Sedar.com page 17
Mar 28 2017 14:27:40 ET Annual information form – English PDF
[url][/url][tag]insert-text-here[/tag]http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00005782
InMed Pharmaceuticals, Inc. (IMLFF) Adds to Its Drug Development Pipeline
April 6, 2017
A pre-clinical stage biopharmaceutical company, InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has revealed two additions to its drug development pipeline. An expedited drug development timeline is now in place for INM-750 for epidermolysis bullosa (EB), with a potential market of about $1 billion. The disease is characterized by fragile skin in children. The company has also announced the development of INM-085 for glaucoma, which represents a potential global market of over $5 billion.
Resulting in a defect in the connective tissue between the dermis and epidermis, most often caused by a lack of keratins, EB currently has no medication-based treatments. Multiple cannabinoids are the active ingredients of INM-750, which is now under development as a topical drug. These were selected to manage keratin levels in people with EB, in which fragile skin can blister and tear easily with the slightest friction or trauma. The cannabinoids were also chosen to address inflammation, itching, wound healing, pain, and skin regeneration.
One of the leading causes of blindness, glaucoma is associated with high fluid pressure in the eye, which can damage the optic nerve. The first glaucoma treatment of its kind, INM-085 will be a multi-target, multi-mechanism therapy. It will contain multiple cannabinoids that can reduce elevated intra-ocular pressure and protect retinal ganglion cells and optic nerve tissues. The drug will be designed to be applied directly to the eye as a topical formulation.
The new drugs in development are in addition to the company’s other initiatives, including a number of cannabinoid-based drugs. Dr. Ado Muhammed, MD, DPM, MFPM, chief medical officer of IMLFF, is a leader in developing cannabinoid therapies. Prior to joining InMed, he served as executive on board at GW Pharmaceuticals (NASDAQ: GWPH), where he was involved in the development and regulatory approval of one of the first prescription cannabis-based drugs on the market. Muhammed has had strategic roles in the research and development, clinical development, and commercialization of specialty drugs.
InMed’s core assets also include a computer-based drug/disease target screening tool and a proprietary cannabinoid manufacturing system. The bioinformatics tool has helped InMed identify novel cannabinoids thanks to algorithms that have allowed the integration of data from various bioinformatics databases. It also uses a database of approved pharmaceutical products and one consisting of over 90 cannabinoid drugs. The company has used the tool to associate approved pharmaceuticals with cannabinoids that have similar structures in order to identify which ones will act on specific genes and proteins.
A biosynthesis system is in development, which is based on similar processes that use bacteria and yeast in industrial applications. It will allow InMed to manufacture naturally occurring cannabinoids in the laboratory at high yields. An alternative to chemical manufacturing methods, it could address production, quality control, purification, and structural integrity. The system is expected to be a revolution in the rapidly emerging cannabinoid pharmaceutical sector.
For more information, visit the company’s website at www.InMedPharma.com
[url][/url][tag]insert-text-here[/tag]https://www.networknewswire.com/inmed-pharmaceuticals-inc-imlff-adds-drug-development-pipeline/
Entrepreneurs, Investors and Medical Professionals Accelerate Interest in Medical and Recreational Cannabis Operations
Apr 6, 2017, 8:45am EDT
PALM BEACH, Florida, April 6, 2017 /PRNewswire/ --
MarketNewsUpdates.com News Commentary
As the business of cannabis continues to develop into a lucrative industry, entrepreneurs, investors and industry advocates are recognizing key opportunities to capitalize on the momentum and steadily rising revenues. A few notable companies in the industry this week include: GW Pharmaceuticals plc (NASDAQ: GWPH), InMed Pharmaceuticals Inc. (OTC: IMLFF) (CSE: IN.CN), Medical Marijuana, Inc. (OTC: MJNA), OWC Pharmaceutical Research Corp. (OTC: OWCP), Terra Tech Corp. (OTC: TRTC).
International Canna Pro Expo Connects Healthcare Professionals, Investors, and Entrepreneurs Interested in the Business of Medical Cannabis - When considering North American sales of medical and recreational cannabis grew by an unprecedented 30% in 2016, the accelerating pace of legalization across the United States, and an ever-expanding list of medicinal uses, it's no surprise why savvy investors are flocking to medical cannabis to claim their stake in the industry.
At the fore front of this financial tidal wave comes the International Canna Pro Expo (ICPE), a medical cannabis industry conference for healthcare and business professionals, June 24 - 25, 2017, at the Sheraton Hotel Downtown in Philadelphia, PA. Read more about ICPE operations at: http://marketnewsupdates.com/news/cpexpo.html
Read More:
[url][/url][tag]insert-text-here[/tag]http://www.bizjournals.com/prnewswire/press_releases/2017/04/06/enUK201704067650
The cost of developing a new pharmaceutical drug exceeds $2.5 billion, according to Tufts University, including $1.4 billion in out-of-pocket expenses and $1.2 billion in opportunity costs for investors. Cannabinoid-based drug development is no exception to these high costs with companies like GW Pharmaceuticals plc (NASDAQ: GWPH) spending nearly $130 million on research and development last year alone.
InMed Pharmaceuticals Inc.’s (CSE: IN) (OTC: IMLFF) bioinformatics platform helps reduce these costs by rapidly identifying cannabinoid compounds to treat specific medical conditions using statistical models.
Pursuing Biosynthesis
InMed Pharmaceuticals has taken a unique low-cost / high-yield approach to developing cannabinoid-based compounds for inclusion in their products. By utilizing the process currently employed to manufacture insulin for diabetes, the company’s strategy can scalably produce a wide range of cannabinoids beyond simply THC and CBD. These cannabinoids could have broad-reaching potential, but haven’t been studied extensively because they are difficult to extract from the cannabis plant at scale.
The company’s process begins by isolating the genes in the cannabis plant that are responsible for producing any specific cannabinoid compound. Next, these genes are injected into a bacteria that acts as a factory for producing those specific cannabinoids at scale. The company can then combine these various compounds to create unique therapies that target specific diseases with the specific cannabinoid(s) that delivers the desired effect.
InMed Pharmaceuticals Inc. (CSE: IN) (OTCQB: IMLFF) aims to leverage its innovative biosynthesis manufacturing technology to unlock the potential of these 90+ other cannabinoids by cost-effectively, safely and scalably producing them in a laboratory setting.
[url][/url][tag]insert-text-here[/tag]http://www.cannabisfn.com/inmeds-bioinformatics-platform-powers-cannabinoid-drug-development/
United States Pancreatic Cancer Pipelines Market Status, Key Player Analysis Upcoming Trends to 2021
Monday, April 3, 2017 2:55
United States Pancreatic Cancer Pipelines Market report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the market.
United States Pancreatic Cancer Pipelines Market 2022, presents critical information and factual data about the United States Pancreatic Cancer Pipelines Market, providing an overall statistical study of the United States Pancreatic Cancer Pipelines Market on the basis of market drivers, United States Pancreatic Cancer Pipelines Market limitations, and its future prospects. The prevalent United States Pancreatic Cancer Pipelines Market trends and opportunities are also taken into consideration in United States Pancreatic Cancer Pipelines Market study.
United States Pancreatic Cancer Pipelines Market 2022 report has Forecast Compound Annual Growth Rate (CAGR) in % value for particular period for United States Pancreatic Cancer Pipelines Market, that will help user to take decision based on futuristic chart. Report also includes key players in United States Pancreatic Cancer Pipelines Market. The United States Pancreatic Cancer Pipelines Market size is estimated in terms of revenue (US$) and production volume in this report. Whereas the United States Pancreatic Cancer Pipelines Market key segments and the geographical distribution is also deeply analysed.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players
Top Key Players Included:
Birken
Fibrocell Science
GlaxoSmithKline
InMed Pharmaceuticals
Karus Therapeutics
RegeneRex Biopharmaceuticals
Scioderm
Shire
Stratatech
[url][/url][tag]insert-text-here[/tag]http://beforeitsnews.com/business/2017/04/united-states-pancreatic-cancer-pipelines-market-status-key-player-analysis-upcoming-trends-to-2021-3245956.html
[url][/url][tag]insert-text-here[/tag]https://www.whatech.com/market-research/medical/279490-new-report-examines-the-united-states-pancreatic-cancer-pipeline-market
InMed Receives Exemption Status from Health Canada
Mar 23, 2015, 08:00 ET from InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 23, 2015 /PRNewswire/-- InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2014, approving InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act.
This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substance and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.
Craig Schneider, President & CEO states, "Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems".
The Office of Controlled Substance licensed dealers has also been notified so that it may import the controlled substances on behalf of InMed.
[url][/url][tag]insert-text-here[/tag]http://www.prnewswire.com/news-releases/inmed-receives-exemption-status-from-health-canada-300054169.html
InMed Pharmaceuticals Forbes Article March 21 2017
InMed Pharmaceuticals Is More Than Just Another Cannabis Drug Company
Debra Borchardt , Forbes Contributor MAR 21, 201
InMed's drugs could generate $6 billion a year in revenue, but the company is also attracting attention for its cannabinoid database and biosynthesis manufacturing. (photo by Shutterstock)
InMed's drugs could generate $6 billion a year in revenue, but the company is also attracting attention for its cannabinoid database and biosynthesis manufacturing. (photo by Shutterstock)
InMed Pharmaceuticals is a Vancouver-based pre-clinical trial biotech company that has not only developed a proprietary cannabinoid manufacturing system, but in the process created a highly sought after database. This database has mapped the different compounds of cannabinoids to the various diseases that it can address.
The database was created by InMed to assist them in their research and has now become a core asset as other biotech companies have come knocking on their door willing to pay for this information. Most medical marijuana processors are using THC and CBD because they are easy to extract in a large volume from the plant, but there are over 90 different cannabinoid structures that InMed has plugged into its system. The bioinformatics algorithm has taken those different compounds and screens them against approved drugs, diseases and genetic profiles of diseases. It then selects specific cannabinoids that might help regulate that particular disease.
This tool is saving time and money in the drug research process. It has already helped InMed to identify two therapies. One for a rare children's skin disease called epidermolysis bullosa (EB) that has no approved treatments and the other for glaucoma. Chief Executive Officer Eric Adams said “It's a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before.”
The company is still in its early stages for these drugs with plans to begin clinical trials in 2018 for the EB drug. It plans to follow on with the glaucoma and pain therapies, but is focusing on the EB treatment first. The EB drug and the glaucoma drug have a potential revenue of $6 billion a year.
InMed is unique for a biotech company because it has more to offer than just a drug pipeline. In addition to the database, they have also developed a method of biosynthesis for cannabinoids that is similar to the one used to create synthetic insulin for millions of diabetic patients. It gives access to minor cannabinoids that are currently not economic to develop into drugs, plus it's cheaper and scalable.
The traditional method is to grow thousands of plants, purify them and process them, which Adams finds to be very unclean. The other end of the spectrum is creating the compound in a chemical lab to recreate structures, which is also time consuming, very expensive and not quite identical to what nature has given. InMed starts with the cannabinoid DNA and actually puts it into a bacteria called E-coli. The E-coli DNA is removed and then the cannabinoid DNA takes over. Like a pharmaceutical copy machine.
Adams said, “It's a tool we created for our ourselves to provide drugs for our own pipeline, but it turns out a lot people are now coming to us wanting to tap into this biosynthesis process as a raw material supplier for their own activity. It will probably be an interesting business for us.” It is expected to be available for labs by the end of this summer.
InMed Pharmaceuticals is a penny stock that trades in the Over-the-Counter market. It has increased 180% over the past year as the company has souped up its board with medical professionals from leading pharmaceutical companies like Eli Lilly and hit the biotech conference circuit. The company also has a former medical director from GW Pharmaceuticals on its team. It's way too early to consider InMed the next GWPH, but it continues to make the right moves to build its reputation and create revenue sources besides the drug pipeline.
“We have a lot on our table right now, but we now have a lot of companies coming to us to access the database and when the time comes they may need us for our raw materials,” said Adams. “InMed's in very unique a position to help enable a large array of pharmaceutical and drug development programs not only for ourselves but for other people to really explore the uses of this drug.”
[url][/url][tag]insert-text-here[/tag]https://www.forbes.com/sites/debraborchardt/2017/03/21/inmed-pharmaceuticals-is-more-than-just-another-cannabis-drug-company/#641775393b22
If Cannabis had a Genome, Inmed Is Mapping It.
Marijuana Trends & ArticlesMar 13, 2017 0 744
As you may or may not know I love Biotech companies as investment opportunities! The reason being is the fact they trade unlike any other companies out there and there are tangible milestones they can hit which when positive send the market into a buying frenzy. In the last year I’ve written about GWPH, ZYNE and CARA which are all Big Board (Nasdaq) companies in Forbes quite successfully and ahead of the market. Today I am writing about INMED, a Canadian based biotech company with board members from Eli Lilly, MIT and a Chief Medical officer formerly of GW Pharmaceuticals who will be the focus of this interview.
InMed has already distinguish themselves as a leading Cannabinoid Pharmaceutical Company. As one of very first biotech companies that entered the Cannabinoid research space, they are uniquely positioned capitalize on the anticipated growth of the cannabis-derived pharmaceutical market by creating not just therapies, but efficient scientific procedures to create those drugs and more importantly patent new methods in the process that are bankable & universal for other companies.
Today I am pleased to bring to the subscribers of Marijuanastocks.com an exclusive interview InMed’s Chief Medical Officer; Dr. Ado Muhammed, MD, DPM, MFPM.
He knows a few things about with cannabinoid based drugs as he is the former Assoc. Medical Director for GW Pharmaceuticals. GW Pharma and was part of the development team that developed Sativex, a cannabinoid based drug for MS that has been approved in over 15 countries worldwide.
Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.
I asked him to explain what InMed is doing and what separates them from Pack.
Q: What initially attracted you to join InMed an earlier stage biotech company involved in cannabis based Pharmaceuticals…an area you have a unique perspective on?
A: Initially it was InMed’s approach to drug discovery using their Bioinformatic program. This precision in the discovery process was a far more advanced approach than I had seen before in my career. The ability to discover compounds intelligently and efficiently to treat disease creates a significant industry advantage for InMed. Also, their drug delivery approach- avoiding systemic exposure through topical/local delivery I believe has a therapeutic advantage over oral delivery in terms of safety and efficacy.
Q: What differentiates InMed from other leading cannabinoid Biotech companies that you have seen?
In addition to the bioinformatics I see two other areas where InMed has an industry advantage. Firstly, using plant equivalent compounds versus others developing synthetic compounds is a clear advantage in my opinion. This will improve the safety profile of InMed’s therapies while providing the efficacious results expected in the treatments. Secondly, the ability to produce cannabinoids in the biosynthesis process
On the other spectrum InMed’s natural compound approach using specifically identified cannabinoids is also unique. This approach vs others using whole plant extracts and oils, is a more efficient method in terms of clinical development. Efficiency in time and cost
A: I understand you were at UBC yesterday getting an update from the team on the biosynthesis program. What essentially is this program and why is it so important for InMed and its shareholders?
Q: Essentially biosynthesis is a process that can manufacture cannabinoids out of a biologic system. This is a well-known system, as evidenced in the manufacturing of insulin, which is used by millions of diabetics daily. Again, I will point to efficiency and precision. Manufacturing cannabinoids in a controlled laboratory environment and eliminating the significant costs and variables associated with the current methods. This will have a major impact on both drug quality & costs. Also, the ability to produce all of the 90+ cannabinoids at a uniform cost open up InMed’s therapeutic potential and will secure our position as a world leader in cannabinoid prescription drug development.
Q: Fast forward 3 years…what are your top 3 indications
A: Of course, Epidermolysis Bullosa our lead therapy. We would expect to be in Phase 3 trials within 3 years and moving quickly to registration. Glaucoma we are targeting to have advanced to a stage where it can be partnered within the next 12 months. I also predict our advancement of other indications within the dermatology/orphan drug space, including the treatment of acute and chronic pain using a topical approach.
4.) Final Thoughts on InMed for our subscribers?
a. InMed has created a tremendous amount of value in a short period as evidenced by the assets in this company. InMed has the opportunity to become a world leader in cannabinoid based medicines and we are well on our way. The team we have assembled has both experience and capabilities to execute on this ambitious goal.
CONCLUSION:
The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020, and while we see the MJ licensed growers offering “medical” marijuana” The big winners in the Cannabis financial space will clearly be the Biotech’s like GWPH, ZYNE, CARA and Vancouver Biotech IMLFF. If you are not familiar with how the US cannabis industry is being tilted towards pharma companies I suggest you read this.
InMed (IMLFF) is a company I have known for a while, actually since I got involved in this space. When I first heard about them and met them two years ago I thought to myself “I wonder how far along they will be in two years?” Well 2 years later and they are positioning themselves in MY OPINION for Buyout or Biotech Glory. They are the frontrunner for Cannabis based Biotech in Canada, but more importantly…….
INMED is completely insulated by Federal, Country or State Law as it relates to Cannabis because at the end of the day they are science based nerds that happen to be mapping the Genome of pot!
If Cannabis had a Genome, Inmed Is Mapping It.
Marijuana Trends & ArticlesMar 13, 2017 0 744
As you may or may not know I love Biotech companies as investment opportunities! The reason being is the fact they trade unlike any other companies out there and there are tangible milestones they can hit which when positive send the market into a buying frenzy. In the last year I’ve written about GWPH, ZYNE and CARA which are all Big Board (Nasdaq) companies in Forbes quite successfully and ahead of the market. Today I am writing about INMED, a Canadian based biotech company with board members from Eli Lilly, MIT and a Chief Medical officer formerly of GW Pharmaceuticals who will be the focus of this interview.
InMed has already distinguish themselves as a leading Cannabinoid Pharmaceutical Company. As one of very first biotech companies that entered the Cannabinoid research space, they are uniquely positioned capitalize on the anticipated growth of the cannabis-derived pharmaceutical market by creating not just therapies, but efficient scientific procedures to create those drugs and more importantly patent new methods in the process that are bankable & universal for other companies.
Today I am pleased to bring to the subscribers of Marijuanastocks.com an exclusive interview InMed’s Chief Medical Officer; Dr. Ado Muhammed, MD, DPM, MFPM.
He knows a few things about with cannabinoid based drugs as he is the former Assoc. Medical Director for GW Pharmaceuticals. GW Pharma and was part of the development team that developed Sativex, a cannabinoid based drug for MS that has been approved in over 15 countries worldwide.
Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.
I asked him to explain what InMed is doing and what separates them from Pack.
Q: What initially attracted you to join InMed an earlier stage biotech company involved in cannabis based Pharmaceuticals…an area you have a unique perspective on?
A: Initially it was InMed’s approach to drug discovery using their Bioinformatic program. This precision in the discovery process was a far more advanced approach than I had seen before in my career. The ability to discover compounds intelligently and efficiently to treat disease creates a significant industry advantage for InMed. Also, their drug delivery approach- avoiding systemic exposure through topical/local delivery I believe has a therapeutic advantage over oral delivery in terms of safety and efficacy.
Q: What differentiates InMed from other leading cannabinoid Biotech companies that you have seen?
In addition to the bioinformatics I see two other areas where InMed has an industry advantage. Firstly, using plant equivalent compounds versus others developing synthetic compounds is a clear advantage in my opinion. This will improve the safety profile of InMed’s therapies while providing the efficacious results expected in the treatments. Secondly, the ability to produce cannabinoids in the biosynthesis process
On the other spectrum InMed’s natural compound approach using specifically identified cannabinoids is also unique. This approach vs others using whole plant extracts and oils, is a more efficient method in terms of clinical development. Efficiency in time and cost
A: I understand you were at UBC yesterday getting an update from the team on the biosynthesis program. What essentially is this program and why is it so important for InMed and its shareholders?
Q: Essentially biosynthesis is a process that can manufacture cannabinoids out of a biologic system. This is a well-known system, as evidenced in the manufacturing of insulin, which is used by millions of diabetics daily. Again, I will point to efficiency and precision. Manufacturing cannabinoids in a controlled laboratory environment and eliminating the significant costs and variables associated with the current methods. This will have a major impact on both drug quality & costs. Also, the ability to produce all of the 90+ cannabinoids at a uniform cost open up InMed’s therapeutic potential and will secure our position as a world leader in cannabinoid prescription drug development.
Q: Fast forward 3 years…what are your top 3 indications
A: Of course, Epidermolysis Bullosa our lead therapy. We would expect to be in Phase 3 trials within 3 years and moving quickly to registration. Glaucoma we are targeting to have advanced to a stage where it can be partnered within the next 12 months. I also predict our advancement of other indications within the dermatology/orphan drug space, including the treatment of acute and chronic pain using a topical approach.
4.) Final Thoughts on InMed for our subscribers?
a. InMed has created a tremendous amount of value in a short period as evidenced by the assets in this company. InMed has the opportunity to become a world leader in cannabinoid based medicines and we are well on our way. The team we have assembled has both experience and capabilities to execute on this ambitious goal.
CONCLUSION:
The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020, and while we see the MJ licensed growers offering “medical” marijuana” The big winners in the Cannabis financial space will clearly be the Biotech’s like GWPH, ZYNE, CARA and Vancouver Biotech IMLFF. If you are not familiar with how the US cannabis industry is being tilted towards pharma companies I suggest you read this.
InMed (IMLFF) is a company I have known for a while, actually since I got involved in this space. When I first heard about them and met them two years ago I thought to myself “I wonder how far along they will be in two years?” Well 2 years later and they are positioning themselves in MY OPINION for Buyout or Biotech Glory. They are the frontrunner for Cannabis based Biotech in Canada, but more importantly…….
INMED is completely insulated by Federal, Country or State Law as it relates to Cannabis because at the end of the day they are science based nerds that happen to be mapping the Genome of pot!
http://marijuanastocks.com/if-cannabis-had-a-genome-inmed-is-mapping-it/
InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference
VANCOUVER, BC / ACCESSWIRE / March 8, 2017 / InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF) announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference, which is being held March 12-15, 2017, at the Ritz Carlton, Laguna Niguel, California.
"The ROTH Conference is one of the largest in the nation, and it does a wonderful job introducing small and mid-cap companies to institutional investors who are focused on these emerging opportunities," said Chris Bogart, SVP of Investor Relations. "InMed Pharmaceuticals is honored to have been asked to present this assembly of Institutional investors who represent significant resources in the healthcare space, and we believe InMed Pharmaceuticals is a very well positioned, high potential opportunity."
About ROTH Capital Conference
ROTH Capital Partners 29th Annual Conference is one of the largest of its kind in the U.S. Following the success of previous years' events, the ROTH Conference, with close to 500 participating companies and over 4,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors including Healthcare. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a 'must attend' event for anyone working in the small and mid-cap space. ROTH combines company presentations, Q&A sessions and management one-on-one meetings so that institutional investors can have an in-depth look at company senior management and issues affecting the growth of the presenting companies.
ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in Boston, Chicago, Larkspur, Los Angeles, New York and San Diego as well as Hong Kong.
[url][/url][tag]insert-thttp://finance.yahoo.com/news/inmed-pharmaceuticals-present-29th-annual-130000606.htmlext-here[/tag]
INMED ANNOUNCES UPDATE ON BIOSYNTHESIS PROJECT
Feb 16, 2016
Vancouver, BC - February 16, 2016 - InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today an update on its biosynthesis program.
The goal of InMed’s biosynthesis program is to provide an alternate low cost and high quality process for producing phytocannabinoids for its product candidates. Typically, phytocannabinoids are extracted from the cannabis plant. The extraction process can be expensive, and can result in unwanted by-products and impurities. Using metabolic engineering the plant pathway for producing cannabinoids can be recreated in a microbial host and will be devoid of the by-products and impurities seen with extraction. The process can also be performed at industrial-scale allowing for a low cost production of cannabinoids.
Dr. Sazzad Hossain states “We have made great progress in the last 8 months developing a comprehensive de novo biosynthesis system for cannabinoids using a multiple metabolic engineering approach and have been able to produce our target cannabinoids on a gram scale basis. Successful production of our target cannabinoids using a biosynthetic process is a significant achievement for InMed and is an important step for our product development program”.
InMed has filed a patent application covering its inventions in the organic and enzymatic synthesis of cannabinoids.
To review a presentation on InMed’s biosynthesis program please click here: http://www.inmedpharma.com/s/presentations.asp
About Metabolic Engineering
Metabolic engineering can be defined as the modification of a cell’s metabolic network for increased production of a specific molecule. Metabolic engineering simply re-creates the plant pathway in a microbial host, thereby allowing industrial-scale exploitation of the pathway for production of natural products. Many of pitfalls associated with plant extraction techniques are avoided. Importantly, unlike plant extraction, metabolic engineering allows manipulation of the pathway composition to tweak the final composition of the products. Not only is it a higher-yielding and more resource-efficient manufacturing platform, but the bioprocess and products face less obstacles when it comes to regulatory approval.
https://www.inmedpharma.com/news-media/news/2016/inmed-announces-update-on-biosynthesis-project/
January 19, 2017 09:00 ET
InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media
SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) recent appointment of Martin Bott to its Board of Directors, the company's existing team, and what it means as InMed progresses towards its first clinical trial in INM-750 for the treatment of Epidermolysis Bullosa as well as the rest of its clinical pipeline.
The appointment of Martin Bott to InMed's Board of Directors represents a strong vote of confidence for its future. Mr. Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK. Prior to his current assignment at Lilly, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations and has been a member of the CFO staff since December 2002.
Mr. Bott joins an already-exceptional Board of Directors including Andrew Hull, another 30+ year Big Pharma executive who is currently the VP of Global Alliances for Takeda Pharmaceuticals; Dr. Bill Garner, a serial biotech entrepreneur who has founded, funded, publicly-listed and divested several companies around the world; Andrew Cutler, a former buy-side Wall Street biotech analyst; and, CEO Eric A. Adams, whose 30+ years in the pharma and biotech industry has seen him serving patients in areas as diverse as HIV/AIDS, organ transplantation, severe burns and oncology.
InMed has made significant progress in developing therapies with certain cannabinoids of the 90+ found in the cannabis plant -- not just THC and CBD -- and has a low-cost process for biosynthesizing these cannabinoids using a method that is similar to the manufacturing process for insulin. This unique approach has drawn the attention of investors, media, and high-profile industry experts.
After making significant progress in 2016, the company is finalizing the transdermal formulation for its Epidermolysis Bullosa (EB) therapy and plans to complete toxicology testing in 2017. The team plans to begin clinical trials in 2018 and will seek an expedited review process with regulatory authorities, including the U.S. FDA, to minimize this product's time-to-market.
Please follow the link to read the full article: http://www.cannabisfn.com/inmed-pharma-appoints-eli-lilly-finance-executive-to-board-of-directors
http://www.marketwired.com/press-release/inmed-pharma-appoints-eli-lilly-finance-executive-to-board-of-directors-cfn-media-otcqb-imlff-2189627.htm
January 19, 2017 09:00 ET
InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media
SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) recent appointment of Martin Bott to its Board of Directors, the company's existing team, and what it means as InMed progresses towards its first clinical trial in INM-750 for the treatment of Epidermolysis Bullosa as well as the rest of its clinical pipeline.
The appointment of Martin Bott to InMed's Board of Directors represents a strong vote of confidence for its future. Mr. Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK. Prior to his current assignment at Lilly, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations and has been a member of the CFO staff since December 2002.
Mr. Bott joins an already-exceptional Board of Directors including Andrew Hull, another 30+ year Big Pharma executive who is currently the VP of Global Alliances for Takeda Pharmaceuticals; Dr. Bill Garner, a serial biotech entrepreneur who has founded, funded, publicly-listed and divested several companies around the world; Andrew Cutler, a former buy-side Wall Street biotech analyst; and, CEO Eric A. Adams, whose 30+ years in the pharma and biotech industry has seen him serving patients in areas as diverse as HIV/AIDS, organ transplantation, severe burns and oncology.
InMed has made significant progress in developing therapies with certain cannabinoids of the 90+ found in the cannabis plant -- not just THC and CBD -- and has a low-cost process for biosynthesizing these cannabinoids using a method that is similar to the manufacturing process for insulin. This unique approach has drawn the attention of investors, media, and high-profile industry experts.
After making significant progress in 2016, the company is finalizing the transdermal formulation for its Epidermolysis Bullosa (EB) therapy and plans to complete toxicology testing in 2017. The team plans to begin clinical trials in 2018 and will seek an expedited review process with regulatory authorities, including the U.S. FDA, to minimize this product's time-to-market.
Please follow the link to read the full article: http://www.cannabisfn.com/inmed-pharma-appoints-eli-lilly-finance-executive-to-board-of-directors/
Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
[url][/url][tag]insert-texthttp://www.marketwired.com/press-release/inmed-pharma-appoints-eli-lilly-finance-executive-to-board-of-directors-cfn-media-otcqb-imlff-2189627.htm-here[/tag]
INMED LAUNCHES NEW WEBSITE
Jan 9, 2017
Dear Shareholders,
InMed is pleased to announce the launch of our newly revamped website. This new redesign offers quick and easy access to essential information including new functionality and enhanced rich content focused on the Company’s mission to be a market leader in cannabinoid based therapies.
Some of the newly created assets can be found on the newly created “Insights” tab. Please access by clicking the link below:
[url][/url][tag]insert-text-here[/tag]https://inmedpharma.com/insights/2017/inmed-pharmaceuticals-video-understanding-cannabinoids/
We believe that this new site will allow our visitors to have a very informative experience as we continue to grow and increase our market presence. The site is located at the same address: [url][/url][tag]insert-text-here[/tag]www.inmedpharma.com
Best Regards
InMed
InMed CEO Discusses R&D Pipeline on BNN
January 10th, 2017
InMed Pharmaceuticals Inc. (OTCQB: IMLFF) (CSE: IN), a pre-clinical biopharmaceutical firm developing novel cannabinoid therapies, was recently featured on Canada’s Business News Network (BNN). In the interview, CEO Eric A. Adams discusses the cannabis plant’s enormous potential for new therapies in the pharmaceutical industry and highlights the company’s R&D pipeline targeting serious medical conditions like Epidermolysis Bullosa (EB) and Glaucoma.
Watch the entire BNN segment here:
In this article, we will look at the company’s approach within the industry and why investors may want to consider the stock right now.
Beyond THC and CBD
InMed Pharma CEO Eric A. Adams noted that there are more than 90 cannabinoids, or individual drugs, present in the marijuana plant during his interview with BNN. Most people have heard of THC and CBD, both of which have significant effects in the human body. And, since THC and CBD account for about 80-90% of cannabinoid drug quantity in the plant and are therefore economically viable to grow-harvest-extract-purify, most companies have focused on developing these two compounds for clinical purposes. The other ‘minor’ cannabinoids tend to occur in very low concentrations in the marijuana plant and are therefore costly and difficult to extract.
InMed is developing a high-yield and low-cost process to biosynthesize cannabinoids utilizing a process that is similar to how insulin is currently mass-produced. The process begins by isolating the genes in the cannabis plant that are responsible for producing specific cannabinoids. Next, these genes are injected into bacteria that act as a factory for producing the cannabinoid at scale. This process enables the company to cost-effectively produce any cannabinoid that may be beneficial in treating human disease. This is truly a 21st century approach to cannabinoid therapeutics.
Expanding R&D Pipeline
InMed Pharma is developing two therapeutics, leveraging combinations of cannabinoids to treat Epidermolysis Bullosa (EB) and Glaucoma. Based on the information provided by the company’s bioinformatics assessment tool, leading to expedited validation in early pre-clinical models, the InMed team chose to focus on EB given that it’s an orphan indication with a significant unmet medical need, tremendously impacting quality of life, and there are no existing treatments or cures. The company hopes to develop a therapeutic that will both treat the devastating symptoms of the disease as well as potentially have a significant impact on the underlying disease itself.
Currently, the company is focused on finalizing the transdermal formulation of the EB therapy, as well as completing some pre-clinical toxicology work on the final product. The team plans to begin clinical trials in about a year and launch the drug in about four years – a shorter than usual timeframe due to the orphan drug status and a potential to ‘fast-track’ the approval process given the therapeutic potential in this horrible disease. In fact, the company estimates that only 200-300 patients will be needed to complete the clinical trials from start to finish…a highly manageable clinical path for a small biotech company and the potential to unlock significant value for shareholders.
Looking Ahead
InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN) has spent the past year validating its drug candidate selection in pre-clinical models, using data to secure patents, and further developing its disruptive technology. In 2017, the company plans to continue the path that it forged in 2016 by furthering the development its two leading products in EB and glaucoma, researching the fundamentals of cannabinoids and their impacts in other diseases with high unmet medical needs, expanding the management team beyond the existing core of biopharmaceutical veterans, and collaborating with seasoned biopharmaceutical investors committed to realizing its potential.
For more information, visit the company’s website at www.inmedpharma.com.
[url][/url][tag]insert-text-here[/tag]http://www.cannabisfn.com/inmed-otcqb-imlff-ceo-discusses-rd-pipeline-on-bnn/
Interesting article By Ross Silver - November 15, 2016
Identifying The Next GW Pharma (Nasdaq: GWPH) Which Went from $8.50 to $132 In a Few Years
With 28 states now legalized for medical marijuana, I believe the focus on Medical Marijuana space will begin to turn to the Cannabis Biotech’s.
What will drive it, increasing access to investment in the space and big winner’s like GW Pharma have paved the way with approved cannabis therapies.
And you can really win in this space given GW Pharma went from $8.50 just a few years ago to close at $132 today.
We believe the Biotechs will be the BIG winners in the Medical MJ space and one we have come across tht caught our eys is InMed Pharmaceuticals (OTCQB: IMLFF), a biopharmaceutical company focused on identifying, developing and commercializing prescription drugs using non-THC cannabinoids. Currently, there are between 80-100 cannabinoids that have been isolated from cannabis that affect the body’s naturally-occurring cannabinoid receptors and are responsible for extensive physiologic effects while having minimal safety concerns.
InMed is utilizing its proprietary bioinformatics program to identify the chemicals within the cannabis plant that interact with certain genes responsible for specific diseases. These newly identified cannabinoid drug candidates promise to significantly reduce side effects while optimizing therapeutic benefits.
Biotech, Big Pharma & Wall Street are actively engaged in Cannabinoid Investment and R&D:
GW Pharmaceuticals– NASDAQ: GWPH
$3.4B mkt cap (as of 11/14/16)
Raised over $700m from BoA, Goldman Sachs, Canaccord Genuity, Morgan Stanley
Zynerba Pharmaceuticals – NASDAQ: ZYNE
$130M mkt cap (as of 11/14/16)
$48m IPO through Piper Jaffray, Leerink , Oppenheimer & Canaccord Genuity
Bayer, Novartis, Otsuka and Abbvie, to name a few, are involved in this cannabinoid specialty sector.
3 Cannabinoid products have been approved by U.S. or European regulatory agencies and they are:
Sativex™ (GW Pharma)
Marinol™ (Insys Therapeutics, ticker: INSY, $975M mkt cap)
Cesamet™ (Meda Pharma, Acquired by Mylan for $7.2B in August 2016)
These are the three Key value drivers of InMed’s portfolio of assets:
Proprietary computer-based drug/disease targeting program
Drug Development
Cannabinoid biosynthesis technology
Proprietary computer-based drug/disease targeting program
InMed is utilizing their novel bioinformatics program to identify which individual chemicals from the cannabis plant can be developed into targeted therapies for specific diseases and conditions. The advantages InMed’s system:
Generates new therapies both quickly and effectively- significant cost and time savings in drug discovery process
Allows InMed to research pharmacological responses of the (significantly under-researched) minor cannabinoids significantly for therapeutic benefits (Most Biotech’s are restricted/limited to researching the 2-or 3 most prevalent cannabinoids out of the 90+ available)
InMed’s system has already identified multiple therapies. InMed’s current drug development focus is on INM-750 & INM-085.
Drug Development
InMed has an extensive portfolio of assets in multi-billion dollar markets such as dermatology & ocular diseases. Their two lead therapies are:
INM-750: Epidermolysis bullosa (EB) is a rare genetic disease characterized by extremely fragile skin that blisters or sheds upon the slightest friction, resulting in extensive open wounds that are slow to heal. INM-750 may be able to reverse EB as it may re-establish the epidermal/dermal junction by upregulation of specific keratins (keratins are proteins that play several roles in skin integrity and function).
INM-085: Glaucoma is an eye disease that manifests as an increase in intraocular pressure which damages ocular nerves and leads to permanent vision loss. Limitations of current therapies include poor adherence and limited efficacy. InMed’s therapy addresses both of these issues as a once-a-day eye drop* with a dual MoA (Mechanism of Action).
* InMed has developed a proprietary nano-particle hydrogel as the delivery system
Cannabinoid biosynthesis technology
The Company is developing a novel biosynthesis (fermentation) process to manufacture pharmaceutical-grade, naturally-occurring cannabinoid drugs in a controlled environment. This proprietary, high-yield process results in higher purity, faster production time and substantially reduced costs when compared to extracting individual cannabinoids from plant material., or when compared to chemical synthesis in a lab setting.
GW Pharma has only identified 14 or so Cannabinoids to develop therapies with. GW uses an extraction methodology. Extraction of cannabinoids from plants has its challenges: Time, cost of harvesting cannabinoid plants coupled with Low extraction yields and high separation costs. Not top mention with farmed organics inconsistent purity & specificity between the batches can require additional blending for final product
The significance of this is InMed’s patent pending biosynthesis production results in pure pharmaceutical grade cannabinoids – any of the 90+ known naturally-occurring cannabinoid
Significant cost savings vs. existing crop extraction & purification methods (GW Pharma’s method)- Lowers Drug production cost!
Enhanced production, purification and QC from current chemical methods
Easier path for Scale-up and systems optimization
Access to minor cannabinoids that are currently economically unfeasible to develop into drugs.
[url][/url][tag]insert-text-here[/tag]http://sylvacap.com/identifying-next-gw-pharma-went-8-50-132-years
InMed Provides 2016 Year End Update
VANCOUVER, Dec. 23, 2016 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, today announced a year end review for 2016.
To Our Valued Shareholders:
First, I wish to express my thanks to all of our shareholders for your continued support of InMed as we build a company in what we believe is the most exciting biotech sector today: cannabinoid-based drug development. As your Company's CEO, I would like to take this opportunity to update you on recent achievements at InMed. Throughout this year, our scientific focus has been directed towards validating our drug candidate selection, using data to secure our patents and further develop key disruptive technologies. I am pleased to report on our last 12 months of achievements in this letter.
Milestones & Progress Achieved in Past Twelve Months:
Strong biopharmaceutical expertise added to Management & Board of Directors
Capital raising to fund continued drug/disease target identification using our proprietary bioinformatics analysis tool
More robust analysis of existing datasets to ensure that our clinical development plans are accurate and positioned to maximize the likelihood for positive outcomes
Validation and advancement of the biosynthesis manufacturing process; filing of provisional patents to commercially protect this key invention
Expanded scope of opportunities for cannabinoid-based drugs by validating new drug/disease targets in in vitro and in vivo efficacy model
Management and Board Additions
InMed has been very successful in attracting highly qualified and extensively experienced biotech and pharmaceutical professionals to both the Management Team and the Board of Directors in 2016. Ms. Alex Mancini, our Sr. VP of Clinical & Regulatory Affairs, has already been very instrumental in solidifying the INM-750 development plan for epidermolysis bullosa (EB) and will continue to direct her efforts primarily towards executing on this program. Dr. Bill Garner (Chairman of the Board) has provided valuable leadership and made several key introductions on behalf of the Company for financings and strategic development. Mr. Andrew Hull (Director) has performed a detailed review of the science and status of drug development programs to help identify potential pathways towards partnerships for our many assets. Our most recent addition, Mr. Jeff Charpentier as CFO, is a 20+ year veteran of the biopharmaceutical sector and will provide valuable leadership in all financial aspects of your Company. Lastly, myself, Eric A. Adams, joined in June 2016 as your President & CEO to navigate the next several stages of corporate growth and position your Company for success. I believe InMed has now assembled an exceptionally qualified and motivated biopharmaceutical management team and Board committed to unlocking the value inherent in the breadth of assets within our Company.
Capital Raising
InMed was successful in completing financings of $1.9M in 2016. Successful fundraising is a team effort and we would not have been able to do this without the leadership and dedication of the three founders of the Company. InMed is now well positioned to attract the new investment required to fund our aggressive growth strategies in 2017.
Epidermolysis Bullosa (EB) Development Program
Data generated in support of the EB program demonstrate that INM-750 may have a significant impact on the symptoms of EB (including accelerated wound healing and a reduction in inflammation, pain (and itch), and act as an anti-bacterial agent). Additionally, our data indicate that INM-750 may have an impact on the underlying disease by increasing keratin production in the skin. Key vendors to support the INM-750 development program have been identified and, in conjunction with access to additional funding in early 2017, we will move quickly to execute on our game plan of optimizing the final formulation, conducting key pre-clinical toxicology (safety) studies, and identifying clinical sites for the initial human clinical trial(s).
Additional Assets
Assets such as the glaucoma drug development program (and, independently, the proprietary, once-per-day nanoparticle hydrogel formulation), the biosynthesis manufacturing process, and other new potential drug/disease targets matured in accordance with our plans during 2016. Together with our several external collaborators, we are exploring every avenue to expedite the advancement of these key assets. Several patents will be filed in 2017, at which time we can begin to publish our data and further validate to the scientific community and investor public the importance of our technologies.
Looking Ahead in 2017
InMed has a tremendous wealth of assets and Management will continue to deploy our financial and human capital towards unlocking their full potential in order bring important new therapies to patients. Our plans in the New Year will continue the path that we have been following in 2016:
Research the fundamental benefits of cannabinoid drugs to treat diseases with high unmet medical needs; selectively advance high-potential drug candidates
Identify and retain seasoned biopharmaceutical veterans to define and execute the drug development programs in a time- and cost-sensitive manner;
Collaborate with biotech-savvy investor groups who are committed to realizing substantial medium and long-term returns on their investment in InMed; explore the partnership potential of the various programs and assets, and, when the ROI is meaningful, move quickly to conclude transactions.
InMed's success depends on your ongoing support and we are grateful for your continued confidence in our mission. We are committed to delivering meaningful scientific and drug innovations that will enhance the value of our Company and reward investors who join us on this journey. I look forward to updating you on the significant progress that InMed will be achieving in 2017
InMed wishes you and your family a joyful holiday season and a Happy New Year!
Eric A. Adams
President & CEO
[url][/url][tag]insert-text-here[/tag]http://www.newswire.ca/news-releases/inmed-provides-2016-year-end-update-608024026.html
InMed announces progress on COPD program
Vancouver, BC - December 6, 2016 - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announced progress today on its R&D program in the use of cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD). In June, 2015 InMed initiated its COPD program using its bioinformatics analysis tool to identify the targets and potential active compounds that can be useful for the treatment of COPD. Subsequently, with in vitro assays using human lung fibroblasts (HFL-1 cell line), InMed has demonstrated that certain cannabinoid compounds are capable of affecting a specific protein in the biochemical pathway relevant to healing and fibrosis in the lung.
Dr. Sazzad Hossain, Chief Scientific Officer of InMed, noted, "Taking into consideration the impact of this specific protein's role in lung tissue remodeling and fibrosis, these preliminary data are important and promising for developing cannabinoid-based therapies for COPD." It is well known that cannabinoids exhibit bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapies may offer safer and more effective treatment options for COPD.
"We continue to make significant scientific progress that further validates InMed's proprietary bioinformatics analysis tool as a cost-effective way to identify drug-disease targets and expedite their validation in pre-clinical models," added Dr. Ado Muhammed, Chief Medical Officer of InMed. "In addition to our primary drug development programs in Epidermolysis Bullosa and Glaucoma, we are pleased to continue to expand the role of cannabinoids in other disease areas."
About Dr. Hossain
Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development at institutions including the University of British Columbia, National Research Council of Canada and Xenon Pharmaceuticals. He is the author of more than 40 peer-reviewed papers, primarily in pharmacology, genetics and nutritional sciences.
insert-text-here
2 Biotech Beauties Poised To Breakout
http://www.investing.com/analysis/two-biotech-beauties-poised-to-breakout-200164273
Epidermolysis Bullosa
insert-text-here
Chris Parry's Inmed analysis release Sept 15, 2016
Here is a copy of Chris Parry's Inmed Analysis he released
"InMed Pharmaceuticals (IN.C): New CEO is a straight up beast"
In the spirit of ‘where are they now’ day comes another in my trilogy of companies I used to write about a lot, that I stopped writing about as they went into hiberation/preparation/organization mode, that have come out swinging in the last week or so.
InMed (IN.C) was once in my medical marijuana top 5. A small outfit built around the magical medication database of Dr Sazzad Hossain, which looks for approved medications that share molecular similarities with elements found in cannabis, in a bid to find ‘fast to approval’ opportunities in the biomed space, the challenge for the company was always going to be two-fold:
1) Keeping investors keen during the slow times in between news (this kind of research isn’t a ‘let’s finish it up before breakfast’ kind of deal)
2) Not running out of money with a company that had no easy monetization path for a while
Well, the previous CEO wasn’t so big on the first one, as news crawled and InMed simply dropped off the radar entirely for most people.
But not all people. One long holder emailed me recently and asked if I knew what was going on.
“I fear I may have lost my investment,” he said. I offered to touch base with the new CEO and see if that was indeed the case.
Holy cow was my timing good.
Eric A. Adams is the new head honcho at InMed, and he’s one of those CEOs that you just wind up and let go. His LinkedIn profile could just be a single huge-fonted word:
BIOPHARM.
Adams knows biotech. A US exec who looked over the InMed story from afar, contacted the team and said, this is very damn interesting to me, he took the reins in June and turned over the furniture from the outset.
“A lot of things needed to change,” he told me. “There’s too much opportunity here and the company needs to be ready when that opportunity starts to ramp up.”
Still in place: Deal guys Craig Schneider and Chris Bogart, who founded the company way back when, and Dr. Sazzad, who (let’s face it) is the company’s only asset of substantial worth. He is the company. The company is Dr Sazzad’s head, tech, and what he’s been doing with it.
So what’s he been doing with it?
Well, that’s information coming soon. Suffice to say, the rubber is hitting the road.
The focus, however, is on Epidermolysis Bullosa, which we’ll call EB from now on because I’m not getting paid by the letter. Or at all.
EB is a skin condition where the epidermis isn’t connecting to the flesh beneath it, resulting in skin that tears like tissue paper. The shitty part of this? There’s no cure. But there is a treatment.
One product, discovered accidentally when an ointment used to keep bandages from sticking was found to have some healing effect, was acquired recently for hundreds of millions of dollars. InMed says the IP they discovered works better, and they’re moving it forward to Phase I soon.
There are other pieces of tech in play, such as a biosynthesis technology that… well, I’ll let them explain it.
The goal of InMed’s biosynthesis program is to provide an alternate low cost and high quality process for producing phytocannabinoids for its product candidates. Typically, phytocannabinoids are extracted from the cannabis plant. The extraction process can be expensive, and can result in unwanted by-products and impurities. Using metabolic engineering the plant pathway for producing cannabinoids can be recreated in a microbial host and will be devoid of the by-products and impurities seen with extraction. The process can also be performed at industrial-scale allowing for a low cost production of cannabinoids.
Dr. Sazzad Hossain states “We have made great progress in the last 8 months developing a comprehensive de novo biosynthesis system for cannabinoids using a multiple metabolic engineering approach and have been able to produce our target cannabinoids on a gram scale basis. Successful production of our target cannabinoids using a biosynthetic process is a significant achievement for InMed and is an important step for our product development program”.
InMed has filed a patent application covering its inventions in the organic and enzymatic synthesis of cannabinoids.
You’re scratching your head, I know, but other companies WANT THIS TECH, and it could be a nice near term earner.
There’s more, but what it all comes down to is, your new CEO is quietly sitting at the end of the boardroom table, not selling, not promising, just laying out a simple game plan that monetizes what InMed has been working on in the fastest way possible, in the area that they’ve decided has the fastest path to approval, with an orphan drug that nobody at the FDA is going to want to impede because BUTTERFLY CHILDREN.
Goddammit, if you can watch that and not want to get behind a company that may just be able to make those kids a little bit closer to whole, you’re a heartless beast.
Take my money. Do the work.
That said, if profit potential is more important to you than humanity, let me say this.
$6 million market cap. $400m acquisition of the only comparable. Share price up 30% since July. Volume jumping hard.
And, oh, then there’s the ongoing buying by insiders who are, deep down, probably pissed that I’m hyping their stock before they can buy it all for themselves.
I said, way back in the day, that it was value added weed plays that would be the big thing that would one day move cannabis into the mainstream, not growers. While growers continue to draw the lion’s share of interest, back at the turn of the 19th century, cannabis was the active ingredient in just about every medication and treatment out there. We lost all that when it was deemed illegal.
Now it’s back, and we have a whole lot of medicine to do. InMed is doing it, and as I press for more information, the new CEO is sitting there, looking at me like Dexter planning his next meal. He knows what this is. He can’t tell me what it is, but I can see he knows. He wants to hit fast forward and get to the part where the rest of us do too. He’s licking his lips and holding down his grin.
InMed Pharma: Game on.
— Chris Parry
www.equity.guru/2016/09/15/inmed-pharmaceuticals-in-c-new-ceo-is-a-straight-up-beast/
InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$304,500
Vancouver, BC – July 28, 2016 - InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB:
IMLFF), further to its release of July 19, 2016 is pleased to announce the closing of a non-brokered
private placement (the “Financing”) for 4,350,000 units (“Units”), at a price of $0.07 per Unit for gross
proceeds of C$304,500.00. Each Unit will consist of one common share and one non-transferable
share purchase warrant (a “Warrant”). Each Warrant will be exercisable by the holder to acquire one
additional common share at a price of $0.15 for a period of twelve (12) months expiring on July 28,
2017. All of the Units issued in connection with the Financing and Common Shares issued on
exercise of the Warrants will be subject to a restricted resale period that expires on November 29,
2016.
Finders’ fees of 7% on a portion of the gross proceeds received by the Company from the sale of
Units sold pursuant to the Financing shall include cash of $1,960.00, and 28,000 warrants (“Agent
Warrants”). Each Agent Warrant shall be exercisable in whole or in part at an exercise price of
$0.15 for a period of 12 months expiring on July 28, 2017.
The proceeds from this private placement will be used for general working capital purposes and a
portion will be used to settle debt.
www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=21434
June 16, 2016 09:02 ET
InMed Announces Appointment of Eric A. Adams as CEO, President and Director
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.
Mr. Adams states, "I'm excited to join InMed at this stage of its development. The assets developed to date by Dr. Sazzad Hossain, InMed's Chief Scientific Officer, and his research collaborators have significant potential for success. InMed's proprietary bioinformatics drug candidate database, its cutting edge cannabinoid biosynthesis program, and active drug development programs in epidermolysis bullosa, glaucoma and other promising disease targets provide an incredibly strong platform for the company's growth through both direct and licensed revenue models; there are short- and medium-term value driving milestones for InMed in all of these areas. We plan to monetize these assets and continue to fund development of important cannabinoid-based drugs for diseases with high unmet medical needs. I look forward to working with the management team and Board to build a successful, diversified drug development company that will tap into the vast potential of cannabinoid therapeutics and contribute to the understanding and commercialization of this important and largely undiscovered class of drugs."
Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs. He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.
Chris Bogart will be stepping down as Interim CEO and resuming his role as SVP of Corporate Strategy and Investor Relations. Additionally, InMed announces it has accepted the resignation of Paul Brennen as a Director of the Company, effective today. The Board wishes to thank Mr. Brennan for his efforts.
2016-06-13 10:16 ET - News Release
Mr. Chris Bogart reports
INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS
InMed Pharmaceuticals Inc. had appointed Dr. William J. Garner, MD, to the board of directors. Dr. Garner is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, mergers and acquisitions, or initial public offering transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as chairman and founder of Update Pharma, and as a director at IGXBio. He has previously served as chief executive officer of Invion Ltd., a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded, and as a co-founder and director of Del Mar Pharmaceuticals. Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche's oncology division. Prior to Roche, Dr. Garner was a health care merchant banker in New York.
He has a master of public health from Harvard and earned his MD at New York Medical College. Dr. Garner did residency training in anatomic pathology at Columbia-Presbyterian and is currently a licensed physician in the state of New York.
"I am excited about joining InMed's board," stated Dr. Garner. "In my review of the drug development programs, which involve topical administration with an inherently reduced risk of systemic toxicity, it became clear that InMed has the potential to achieve important, value-driving milestones in diseases with high unmet medical needs. The ultraorphan lead indication is a particularly attractive opportunity, in my opinion. Together with the directors and management of the company, I believe my skill sets can augment InMed's efforts to optimize the development pathway and monetize its many assets."
InMed also announces it has accepted the resignation of Steve Tong as a director of the company, effective today. The board wishes to thank Mr. Tong for his efforts on behalf of the company.
May 18, 2016
InMed Updates Progress of its Epidermolysis Bullosa Program
www.inmedpharma.com/s/news-releases.asp?ReportID=749413&_Type=Press-Releases&_Title=InMed-Updates-Progress-of-its-Epidermolysis-Bullosa-Program
New Pre-clinical Results of Pain Relieving Properties of INM-750
Vancouver, BC - May 18, 2016 - InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies is pleased to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that has been specifically designed to: (i) modify the underlying cause of the disease in patients with epidermolysis bullosa simplex (EBS, the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed is now pleased to report that INM-750 has demonstrated positive pain relieving effects in animal models. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, "I am very excited with these results as pain is a serious complication in EB and this animal data shows that INM-750 reduces both acute and chronic pain. Significant data has been previously generated and reported to demonstrate the diverse properties of INM-750 in wound healing, skin regeneration, anti-inflammation and its antibacterial effects. Together with pain, these disease hallmarks are key therapeutic targets for the effective treatment of EB as well as several other dermatological conditions."
A summary of the pre-clinical results on INM-750, a non-THC cannabinoid based composition, is available on InMed's website under the Investors and the Pipeline sections.
News..should get interesting this year and well into future
https://ca.finance.yahoo.com/news/bee-vectoring-technologies-provides-company-140500218.html
News 11/17/15
Bee Vectoring on the Brink of Revolutionizing the Agricultural Sector
http://www.newswire.ca/news-releases/bee-vectoring-on-the-brink-of-revolutionizing-the-agricultural-sector-551021711.html
Acquisition Rumours
Claude Fluckinger, Director, Bee Vectoring Technologies International , who is also the head of global product biology for Syngenta AG’s lawn and garden division, says there is a precedent for a lucrative buyout, since most big chemical firms don’t do very much research in the field of biology and usually opt to buy up small firms.
http://www.bnn.ca/News/2015/9/18/Acquisition-rumours-are-buzzing-around-this-venture-listed-bee-business.aspx
Claude Fluckinger profile
https://www.linkedin.com/in/claudeflueckiger
Syngenta (Swiss-based fertilizer company recently offered US$46.5 billion in an August takeover bid by Monsanto). Monsanto has made an increased takeover offer to Syngenta AG, seeking to draw the Swiss pesticide producer to the negotiating table after its earlier approach was rejected.
What cannot be lost, from an investor's standpoint, is this: Companies such as Monsanto and Bayer are being blasted by many media and activist groups, and even boycotted by some consumers, for their use of controversial pesticides. To save the bees, it appears scientists must find a way to sustainably grow and control crop yields without the use of harmful pesticides. One small-cap company based in Ontario, Canada, which only this July went public, has developed and owns patent-pending bee vectoring technology (consisting of a proprietary tray dispenser containing a unique carrier agent). This is designed to harmlessly utilize commercially reared bumblebees as natural delivery mechanisms, without water, for a variety of powdered mixtures comprised of organic compounds that inhibit or eliminate common crop diseases, while at the same time stimulating and enhancing the same crops. This unique and proprietary process facilitates a targeted delivery of crop controls using the simple process of bee pollination to replace traditional crop spraying, resulting in better yield, organic product and less impact on the environment without the use of water or disruptions to labour.